seen from Portugal
seen from United States
seen from Mexico
seen from Singapore
seen from Malaysia
seen from United States
seen from Vietnam
seen from Japan
seen from United States
seen from United States
seen from United Kingdom
seen from Philippines
seen from Singapore
seen from United Arab Emirates
seen from United States
seen from United States
seen from United Kingdom
seen from Japan
seen from United States
seen from Saudi Arabia
AbbVie ($ABBV) got a chance on Sunday to start explaining just why it was inspired to pay a whopping $5.8 billion upfront - with $4 billion reserved for milestones - for Stemcentrx and its overnight cancer drug sensation Rova-T.
My comment on today's less than spectacular Rova-T data included in the above story.
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
AbbVie Agrees to Buy Stemcentrx
AbbVie Agrees to Buy Stemcentrx
April 28, 2016
Pharmaceutical company AbbVie Inc. has agreed to acquire Stemcentrx Inc., a cancer-drug developer, for $5.8 billion. This is part of AbbVie’s continuing aggressive push for building an oncology business.
AbbVie gains Stemcentrx’s experimental treatment for a form of lung cancer, plus other experimental drugs. It also involves cash-and-stock acquisition, which includes potential…
View On WordPress
